Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial

Inflammation has been associated with increased morbidity and mortality in HIV-positive patients. We compared inflammatory biomarkers with dual therapy using lopinavir/ritonavir plus lamivudine (LPV/r+3TC) versus triple therapy using LPV/r plus two nucleoside reverse transcriptase inhibitors (LPV/r+...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2019-09, Vol.14 (9), p.e0221653-e0221653
Hauptverfasser:	Tan, Darrell H S, Rolon, Maria Jose, Figueroa, Maria Ines, Sued, Omar, Gun, Ana, Kaul, Rupert, Raboud, Janet M, Szadkowski, Leah, Hull, Mark W, Walmsley, Sharon L, Cahn, Pedro
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome Adult Adults AIDS Analysis Antiretroviral agents Antiretroviral drugs Antiviral drugs Biological markers Biology and Life Sciences Biomarkers Biomarkers - metabolism CD4 antigen Clinical trials Dimers DNA polymerases Dosage and administration Drug therapy Female Health care networks HIV HIV infections HIV Infections - drug therapy HIV Infections - metabolism Hospitals Human immunodeficiency virus Humans Infections Infectious diseases Inflammation Inflammation - metabolism Interleukin 6 Lamivudine Lopinavir Lopinavir - therapeutic use Male Medical research Medicine and Health Sciences Middle Aged Monocyte chemoattractant protein 1 Morbidity Mortality Nucleoside reverse transcriptase inhibitors Nucleosides Randomized Controlled Trials as Topic Reverse transcriptase inhibitors Ritonavir Ritonavir - therapeutic use RNA-directed DNA polymerase Sexually transmitted diseases Statistical analysis STD Therapy Time Factors Treatment Outcome Tumor necrosis factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!